NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
65597-0511-04 | 65597-0511 | QUIZARTINIB | VANFLYTA | 26.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | Jul 20, 2023 | In Use | |
00378-6678-28 | 00378-6678 | Sunitinib malate | Sunitinib Malate | 12.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Jan 4, 2022 | In Use | |
00378-2245-77 | 00378-2245 | imatinib | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 28, 2017 | In Use | |
43598-0604-30 | 43598-0604 | Dasatinib | Dasatinib | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
57962-0140-12 | 57962-0140 | Ibrutinib | Imbruvica | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Oral | Nov 13, 2013 | In Use | |
00003-0527-11 | 00003-0527 | Dasatinib | Sprycel | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jun 27, 2006 | In Use | |
60505-2900-08 | 60505-2900 | Imatinib Mesylate | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 5, 2016 | In Use | |
00832-0533-03 | 00832-0533 | Imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | May 17, 2024 | In Use | |
59651-0532-03 | 59651-0532 | Erlotinib | Erlotinib | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jun 22, 2022 | In Use | |
00054-0249-22 | 00054-0249 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 28, 2018 | In Use | |
57962-0070-28 | 57962-0070 | Ibrutinib | IMBRUVICA | 70.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Oral | Dec 20, 2017 | In Use | |
54868-5289-04 | 54868-5289 | Imatinib Mesylate | Gleevec | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Oct 7, 2005 | Jun 30, 2013 | No Longer Used | |
76189-0113-18 | 76189-0113 | Brigatinib | Alunbrig | 30.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK/ROS1/ EGFR | Oral | Apr 28, 2017 | Dec 12, 2020 | No Longer Used |
00069-1500-60 | 00069-1500 | CRIZOTINIB | Xalkori | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK, HGFR, ROS1, RON | Oral | Nov 20, 2023 | In Use | |
70710-1742-06 | 70710-1742 | Dasatinib | Dasatinib | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
65162-0794-09 | 65162-0794 | Imatinib | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 8, 2019 | In Use | |
42291-0939-12 | 42291-0939 | Pazopanib | Pazopanib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, PDGFR, FGFR, Kit, Itk, Lck, c-Fms | Oral | Apr 23, 2024 | In Use | |
67877-0634-30 | 67877-0634 | imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 1, 2019 | In Use | |
72485-0203-30 | 72485-0203 | imatinib mesylate | Imatinib mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 15, 2019 | In Use | |
70771-1394-09 | 70771-1394 | Imatinib mesylate | Imatinib mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Jan 21, 2021 | In Use | |
59651-0464-28 | 59651-0464 | SUNITINIB MALATE | SUNITINIB MALATE | 12.5 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, CSF | Oral | Mar 14, 2024 | In Use | |
69539-0090-30 | 69539-0090 | Erlotinib Hydrochloride | Erlotinib Hydrochloride | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 11, 2021 | In Use | |
00078-0698-99 | 00078-0698 | RYDAPT | Rydapt | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Oral | Apr 28, 2017 | In Use | |
50242-0130-86 | 50242-0130 | ALECTINIB HYDROCHLORIDE | Alecensa | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Oral | Oct 10, 2017 | In Use | |
00069-8140-20 | 00069-8140 | Crizotinib | Xalkori | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK | Oral | Aug 26, 2011 | In Use |
Found 11465 results — Export these results